In a preclinical study, silibinin was found to downregulate PD-L1 expression by modulating HIF-1α/LDH-A mediated cell metabolism in NPC cells offering a rationale for using silibinin to overcome PD-L1 mediated NPC drug resistance [249]. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.